Evidence map›Paper›PMID 36303933›Full record

ReviewHeliyon2022

Cell cycle associated miRNAs as target and therapeutics in lung cancer treatment.

Atqiya Fariha, Ithmam Hami, Mahafujul Islam Quadery Tonmoy, Shahana Akter, Hasan Al Reza, Newaz Mohammed Bahadur, Md Mizanur Rahaman, Md Shahadat Hossain

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Heliyon, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. miRNA-Based Technologies in Cancer Therapy.Journal of personalized medicine · 2023
    Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Atqiya FarihaDepartment of Biotechnology & Genetic Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.
Ithmam HamiDepartment of Biotechnology & Genetic Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.
Mahafujul Islam Quadery TonmoyDepartment of Biotechnology & Genetic Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.
Shahana AkterDepartment of Biotechnology & Genetic Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.
Hasan Al RezaDepartment of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh.
Newaz Mohammed BahadurDepartment of Applied Chemistry and Chemical Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.
Md Mizanur RahamanDepartment of Microbiology, University of Dhaka, Dhaka, Bangladesh.
Md Shahadat HossainDepartment of Biotechnology & Genetic Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.
Noakhali Science and Technology University · BDUniversity of Dhaka · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the primary cause of cancer related deaths worldwide. Limited therapeutic options and resistance to existing drugs are the major hindrances to the clinical success of this cancer. In the past decade, several studies showed the role of microRNA (miRNA) driven cell cycle regulation in lung cancer progression. Therefore, these small nucleotide molecules could be utilized as promising tools in lung cancer therapy. In this review, we highlighted the recent advancements in lung cancer therapy using cell cycle linked miRNAs. By highlighting the roles of the specific cell cycle core regulators affiliated miRNAs in lung cancer, we further outlined how these miRNAs can be explored in early diagnosis and treatment strategies to prevent lung cancer. With the provided information from our review, more medical efforts can ensure a potential breakthrough in miRNA-based lung cancer therapy.

Indexed as

BiomarkerCancer therapyCell cyclemiRNANSCLC

Identifiers

PMID36303933
PMCPMC9593298
OpenAlexW4306146199

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.